One out of every three breast cancer patients in India may be able to avoid chemotherapy if tests are available in India at reasonable cost to predict the risk of recurrence of the disease. These tests, of which Oncotype DX is the most validated one, are prohibitively expensive.
“Only about 5% of our patients are able to afford the Oncotype DX test. It costs around Rs 3 lakh,” Dr S V S Deo, professor and head of surgical oncology at AIIMS, said. “For the rest, we use our clinical assessment to decide if they need chemotherapy or not,” he added. Even in the private sector, only about 20% of patients are able to afford such tests, said Dr P K Julka, senior director, Max Daycare Oncology Centre. Oncotype DX has been available abroad for nearly a decade. It can predict the risk of recurrence on a scale of 0 to 100 by assessing 21 genes associated with the disease.
It has been known for long that women who fall between 0 and 10 have a very low risk of recurrence and those who fall between 26 and 100 are at high risk. But there was no consensus on risk of recurrence for those falling in between these two categories — those who got from 11 to 25. A recent research published in The New England Journal of Medicine, that was supported by US’ National Cancer Institute, has validated that women falling in the 11-25 score group are also at low risk for recurrence and may not need chemotherapy.
Most breast cancer patients, nearly 70% of them, fall in this category and experts abroad said they will benefit from the findings. However, in India, doctors said even if the tests were available, not more than 30-35% patients would be a candidate for the testing. “Nearly 50% of patients are diagnosed for breast cancer in advanced stages in India. Among the remaining half, 30-35% may require undergoing Oncotype DX test to predict risk of recurrence and chemotherapy need,” Dr Deo said.
In the US and other developed nations, most patients are diagnosed with breast cancer at early stages and, therefore, they can benefit more from such tests.
You must be logged in to post a comment.